Basis: Four-quarter free cash flow / FMP quote market capitalization × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The free cash flow yield is N/A as of 2026-10-06T19:42:37.671Z.
Calculation as of: 2026-10-06T19:42:37.671Z.
Quote observation: 2026-10-06T19:40:04.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: f827d960650d67e3900ac6098f04a5e2078fd3b8121965df68c70cd2fd602cdf
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
FREE CASH FLOW YIELD
N/A
Anbio Biotechnology Class A Ordinary Shares
Market Cap
$210.90M
Free Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$210.02M
Free Cash Flow Yield
N/A
TTM Avg
24.58%
3Y Avg
24.58%
5Y Avg
24.58%
Market Cap
$209.25M
Free Cash Flow Yield
3.29%
TTM Avg
3.60%
3Y Avg
5.22%
5Y Avg
5.17%
Market Cap
$210.85M
Free Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$212.25M
Free Cash Flow Yield
2.67%
TTM Avg
2.46%
3Y Avg
2.61%
5Y Avg
2.53%
Market Cap
$212.74M
Free Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$214.35M
Free Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$205.44M
Free Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | FREE CASH FLOW YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Anbio Biotechnology Class A Ordinary Shares (NNNN) | $210.90M | N/A | N/A | N/A | N/A |
| Compugen Ltd. (CGEN)vs › | $210.85M | N/A | N/A | N/A | N/A |
| Entrada Therapeutics, Inc. (TRDA)vs › | $210.02M | N/A | 24.58% | 24.58% | 24.58% |
| Pro-Dex, Inc. (PDEX)vs › | $209.25M | 3.29% | 3.60% | 5.22% | 5.17% |
| Sionna Therapeutics, Inc. (SION)vs › | $210.85M | N/A | N/A | N/A | N/A |
| Niagen Bioscience Inc (NAGE)vs › | $212.25M | 2.67% | 2.46% | 2.61% | 2.53% |
| Lyell Immunopharma, Inc. (LYEL)vs › | $212.74M | N/A | N/A | N/A | N/A |
| Prelude Therapeutics Incorporated (PRLD)vs › | $214.35M | N/A | N/A | N/A | N/A |
| Electra Therapeutics Inc. (ETRA)vs › | $205.44M | N/A | N/A | N/A | N/A |
| Whitehawk Therapeutics Inc (WHWK)vs › | $204.38M | N/A | 0.34% | 0.34% | 0.34% |
FCF Yield
N/A
Earnings Yield
N/A
Dividend Yield
N/A
Formula: FCF Yield = (Free Cash Flow / Market Cap) × 100
How FCF Yield is used:
FCF vs earnings: Differences between FCF yield and earnings yield can reflect capital expenditures, working capital changes, and other non-cash accounting items.
FCF Yield measures free cash flow relative to market capitalization. It compares cash generation after capital expenditures with the equity value of the company.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
